RLM Realm Thera.

TIDMPURI

PuriCore Plc

15 November 2012

15 November 2012

PuriCore plc

("PuriCore" or the "Company")

PuriCore Partners with Lohas Products GmbH for Water Treatment Marketing

Market development will target food production, foodservice, and agriculture markets

PuriCore (LSE: PURI), the water-based clean technology company, today announces a marketing and distribution agreement with Lohas Products GmbH, a German-based innovative provider of special individualized solutions for food safety and water treatment products. PuriCore will provide technical and scientific knowledge as new applications are commercialised, and Lohas will have an exclusive license to market and distribute the applications in certain markets and territories (exclusive of the US and UK). These new potential applications include but are not limited to the use of PuriCore's technology for seafood production, water treatment in restaurants, and livestock husbandry. Collaboration on marketing plans and application development will be ongoing in 2013 with revenue generation no later than 2014.

Under the terms of the agreement, PuriCore and Lohas will equally share profits of the products as they are commercialised. PuriCore will update the market on further details as the businesses are developed.

Michael Ashton, Executive Chairman of PuriCore, said:

"Our water-based disinfectant technology has a multitude of potential applications to help control the spread of infectious pathogens on farms, in restaurants, and in factories. Today's agreement will provide access to the proven distribution network of Lohas to bring new products successfully to market in new international territories."

Oliver Winter, General Manager, Lohas Products GmbH, said:

"We are especially happy that in PuriCore we have found a strategic partner with such an extensive understanding and expertise for the needs and potential added values for our client-base. We are convinced that together we can offer innovative solutions for a whole variety of demands in the industries in which we have decade-long relationships to a wide variety of potential customers of PuriCore's broad portfolio."

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary solutions that protect people from the spread of infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon effective pathogen control. PuriCore is the leading full provider of all products and services required for a safe, efficient, and compliant endoscope decontamination to protect patients in UK hospitals. The Company's products are the de facto standard for food safety in leading US supermarket chains. PuriCore also offers a breakthrough wound therapy solution to treat chronic and acute wounds including diabetic ulcers and burns. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK. To receive additional information on PuriCore, visit www.puricore.com, which does not form part of this press release.

About Lohas

LOHAS, a German-based company, is special solutions provider that has through its shareholders, clients and strategic partners, a wide globally connected network foremost in the fields of food production and distribution as well as gastronomy franchises. It offers highly individualized solutions for its clients throughout the whole production process and value chain. Lohas is headquartered in Hamburg, Germany.

Enquiries:

   UK                                            US 
   FTI Consulting                          Sage Strategic Marketing 
   Susan Stuart                             Jennifer Guinan 
   Simon Conway                          +1 610.410.8111 

+44 (0) 20 7831 3113

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAGGGBGGUPPPWC

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Realm Thera. (LSE:RLM)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024